
FDA Expands Approval for J&J’s Spravato as Standalone Depression Treatment
Prime Highlights: The FDA has approved Johnson & Johnson’s Spravato (esketamine) nasal spray for standalone
Prime Highlights: The FDA has approved Johnson & Johnson’s Spravato (esketamine) nasal spray for standalone
Prime Highlights: Researchers led by 2024 Nobel Laureate David Baker develop AI-designed proteins that neutralize
Prime Highlights: Washington University research identifies a potential new use for an existing drug. RSK1
Prime Highlights: Medicare’s new $2,000 cap on out-of-pocket prescription drug costs could save patients thousands.
Prime Highlights: UnitedHealth reports Q4 earnings of $6.81 per share, exceeding estimates of $6.72. Health
Prime Highlights: Pfizer to sell $3.05 billion worth of shares in Haleon, reducing its stake
Prime Highlights: Eli Lilly to acquire Scorpion Therapeutics’ experimental cancer therapy, STX-478, for up to
Prime Highlights: Telix secures a US$45 million ($73 million) deal to acquire US-based antibody engineering
Prime Highlights: DBAY Advisors, an asset management firm, has agreed to acquire UK-based Alliance Pharma
Prime Highlights: Medicare will now cover Eli Lilly’s Zepbound for obstructive sleep apnea, following FDA